| Dr Michael Patrick Greenwood, MD | |
|
909 Fulton St Se, Minneapolis, MN 55455-4800 | |
| (612) 672-7422 | |
| Not Available |
| Full Name | Dr Michael Patrick Greenwood |
|---|---|
| Gender | Male |
| Speciality | Pathology - Clinical Pathology/laboratory Medicine |
| Location | 909 Fulton St Se, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023379419 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZC0006X | Pathology - Clinical Pathology | R8003 (Texas) | Secondary |
| 207ZP0105X | Pathology - Clinical Pathology/laboratory Medicine | 70766 (Minnesota) | Primary |
| Entity Name | University Of Minnesota Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477598118 PECOS PAC ID: 9830001189 Enrollment ID: O20031104000532 |
News Archive
Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.
The DNA Medicine Institute, a commercial organization focused on advancing human health through innovation, today announced that it has been awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.
Most people with depression are initially treated with antidepressants, and prescribing has risen by 253% in 10 years. Yet recent studies show that SSRIs have no clinically meaningful advantage over placebo, write Joanna Moncrieff and Irving Kirsch.
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites - most notably, raccoon roundworms (Baylisascaris procyonis).
› Verified 1 days ago
| Entity Name | Healtheast Medical Research Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639125503 PECOS PAC ID: 3971407636 Enrollment ID: O20031124000507 |
News Archive
Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.
The DNA Medicine Institute, a commercial organization focused on advancing human health through innovation, today announced that it has been awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.
Most people with depression are initially treated with antidepressants, and prescribing has risen by 253% in 10 years. Yet recent studies show that SSRIs have no clinically meaningful advantage over placebo, write Joanna Moncrieff and Irving Kirsch.
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites - most notably, raccoon roundworms (Baylisascaris procyonis).
› Verified 1 days ago
| Entity Name | Fairview Express Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053952606 PECOS PAC ID: 3375645179 Enrollment ID: O20081028000548 |
News Archive
Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.
The DNA Medicine Institute, a commercial organization focused on advancing human health through innovation, today announced that it has been awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.
Most people with depression are initially treated with antidepressants, and prescribing has risen by 253% in 10 years. Yet recent studies show that SSRIs have no clinically meaningful advantage over placebo, write Joanna Moncrieff and Irving Kirsch.
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites - most notably, raccoon roundworms (Baylisascaris procyonis).
› Verified 1 days ago
| Entity Name | University Of Minnesota Health Clinics And Surgery Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053795187 PECOS PAC ID: 9133423304 Enrollment ID: O20160209000524 |
News Archive
Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.
The DNA Medicine Institute, a commercial organization focused on advancing human health through innovation, today announced that it has been awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.
Most people with depression are initially treated with antidepressants, and prescribing has risen by 253% in 10 years. Yet recent studies show that SSRIs have no clinically meaningful advantage over placebo, write Joanna Moncrieff and Irving Kirsch.
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites - most notably, raccoon roundworms (Baylisascaris procyonis).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Patrick Greenwood, MD 6565 Fannin St, M227, Pathology & Genomic Medicine, Houston, TX 77030-2703 Ph: () - | Dr Michael Patrick Greenwood, MD 909 Fulton St Se, Minneapolis, MN 55455-4800 Ph: (612) 672-7422 |
News Archive
Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.
The DNA Medicine Institute, a commercial organization focused on advancing human health through innovation, today announced that it has been awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.
Most people with depression are initially treated with antidepressants, and prescribing has risen by 253% in 10 years. Yet recent studies show that SSRIs have no clinically meaningful advantage over placebo, write Joanna Moncrieff and Irving Kirsch.
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites - most notably, raccoon roundworms (Baylisascaris procyonis).
› Verified 1 days ago
Khalid Amin, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 420 Delaware St Se, C463 Mayo Memorial Bldg, Mayo Mail Code 76, Minneapolis, MN 55455 Phone: 913-827-3505 | |
Dr. Laura L Schmitz, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Minneapolis, MN 55422 Phone: 763-581-4150 Fax: 763-581-4151 | |
Deborah Elizabeth Powell, MD Pathology Medicare: Medicare Enrolled Practice Location: 500 Harvard St Se, Lab Med & Pathology, Minneapolis, MN 55455 Phone: 612-273-1142 | |
Yiang Hui, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave S Ste 2200, Minneapolis, MN 55407 Phone: 612-767-8373 | |
Dr. Pamela Ann Sakkinen, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave S Ste 2200, Hospital Pathology Assoc, Minneapolis, MN 55407 Phone: 612-767-8370 Fax: 612-767-8376 | |
Kevin Todd Stieglbauer, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave S Ste 2200, Hospital Pathology Assoc, Minneapolis, MN 55407 Phone: 612-767-8370 Fax: 612-767-8376 |